Delving into the Latest Updates on Shanghai Fengxian District Central Hospital with Synapse

Safety and efficacy of recombinant L-IFN adenovirus injection in relapsed/refractory solid tumors: a single/multicenter, dose-increasing, cohort extension clinical study

开始日期2022-03-14

申办/合作机构

Shanghai Fengxian District Central Hospital

NCT05179733 / Recruiting临床3期IIT

The Efficacy and Safety of Zanubrutinib, Rituximab and Lenalidomide (ZR2) Versus Rituximab Combined With Low-dose CHOP (R-miniCHOP) in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 Years: A Multicenter, Prospective, Randomized, Open-label, Controlled Trial

A multicenter, prospective, randomized, open-label, controlled trial to evaluate the efficacy and safety of zanubrutinib, rituximab and lenalidomide (ZR2) versus rituximab combined with low-dose CHOP (R-miniCHOP) in the treatment of unfit or frail de novo diffuse large B-cell lymphoma patients aged older than or equal to 70 years

开始日期2022-03-02

申办/合作机构

上海交通大学医学院附属瑞金医院

[+20]

NCT05180851 / Unknown status早期临床1期IIT

Safety and Efficacy of Recombinant L-IFN Adenovirus Injection in Relapsed/Refractory Solid Tumors: a Single/Multicenter, Dose-increasing, Cohort Extension Clinical Study

This is an open-label, dose escalation study of the safety and tolerability of Recombinant oncolytic adenovirus L-IFN injection（YSCH-01） when administered via intratumoral injection in patients with advanced solid tumors. The purpose of this study is to assess the safety and tolerability of Recombinant L-IFN adenovirus injectionand to determine the recommended phase 1 dose for further study. The study will also evaluate antitumor activity, objective response rate, pharmacokinetics and virus shedding of Recombinant L-IFN adenovirus injection

开始日期2021-11-30

申办/合作机构

Shanghai Fengxian District Central Hospital

[+1]

100 项与 Shanghai Fengxian District Central Hospital 相关的临床结果

登录后查看更多信息

0 项与 Shanghai Fengxian District Central Hospital 相关的专利（医药）

登录后查看更多信息

187

项与 Shanghai Fengxian District Central Hospital 相关的文献（医药）

2024-09-10·Asian journal of surgery

A case of Type II Abernethy malformation with multiple intrahepatic nodules.

Letter

作者: Pan, Haibin ; Kong, Linghang ; Li, Xiaobing ; Pan, Jingjiang

2024-09-01·Asia Pacific journal of clinical nutrition

Nasogastric tube versus postpyloric tube feeding for critical illness: A systematic review and meta-analysis.

Review

作者: Li, Liru ; Huang, Jie

BACKGROUND AND OBJECTIVESGastric tube feeding and postpyloric tube feeding are two common forms of enteral nutrition in critically ill patients. This study aimed to compare the efficacy and safety of gastric tube feeding with that of postpyloric tube feeding in critically ill patients.METHODS AND STUDY DESIGNPubMed, Embase, and Cochrane Library were systematically searched for eligible trials from their inception until March 2023. Relative risks (RRs) or weighted mean differences (WMDs) with 95% confidence intervals (CIs) were used to estimate categorical and continuous outcomes using the random-effects model.RESULTSSixteen trials involving 1,329 critically ill patients were selected for the final meta-analysis. Overall, we noted that gastric tube feeding showed no significant difference from post-pyloric tube feeding in mortality (p = 0.891), whereas the risk of pneumonia was significantly increased in patients who received gastric tube feeding (RR: 1.45; p = 0.021). Furthermore, we noted that gastric tube feeding was associated with a shorter time required to start feeding (WMD: -11.05; p = 0.007).CONCLUSIONSThis research revealed that initiating feeding through the gastric tube required less time compared to postpyloric tube feeding. However, it was also associated with a heightened risk of pneumonia among critically ill patients.

2024-05-02·Oncogene

Downregulation of UBB potentiates SP1/VEGFA-dependent angiogenesis in clear cell renal cell carcinoma

Article

作者: Zhang, Wenfu ; Wang, Jinpeng ; You, Bosen ; Li, Xuedong ; Zhao, Enyang ; Liu, Weiyang ; Zhang, Wei ; Liu, Qing ; Geng, Bo ; Hou, Wenbin ; Zhang, Nan ; Li, Zhuolun ; Liu, Zhiming ; Wu, Pengfei

AbstractClear cell renal cell carcinoma (ccRCC) presents a unique profile characterized by high levels of angiogenesis and robust vascularization. Understanding the underlying mechanisms driving this heterogeneity is essential for developing effective therapeutic strategies. This study revealed that ubiquitin B (UBB) is downregulated in ccRCC, which adversely affects the survival of ccRCC patients. UBB exerts regulatory control over vascular endothelial growth factor A (VEGFA) by directly interacting with specificity protein 1 (SP1), consequently exerting significant influence on angiogenic processes. Subsequently, we validated that DNA methyltransferase 3 alpha (DNMT3A) is located in the promoter of UBB to epigenetically inhibit UBB transcription. Additionally, we found that an unharmonious UBB/VEGFA ratio mediates pazopanib resistance in ccRCC. These findings underscore the critical involvement of UBB in antiangiogenic therapy and unveil a novel therapeutic strategy for ccRCC.

100 项与 Shanghai Fengxian District Central Hospital 相关的药物交易

登录后查看更多信息

100 项与 Shanghai Fengxian District Central Hospital 相关的转化医学

登录后查看更多信息